不同中枢神经系统脱髓鞘疾病的MRI病灶演变比较
本研究回顾性纳入Mayo Clinic的156例MOGAD、AQP4-IgG-NMOSD或MS患者(172次发作),比较急性期与随访MRI上T2病灶的转归。结果显示MOGAD的T2病灶完全消失更常见,脑部及脊髓病灶消失比例均高于AQP4-IgG-NMOSD和MS,且脑部病灶面积缩小更显著。
要点
- MOGAD的T2病灶完全消失率高于AQP4-IgG-NMOSD和MS。
- 脊髓病灶在AQP4-IgG-NMOSD和MS中均未观察到完全消失。
- 随访脑MRI中MOGAD病灶面积缩小程度大于AQP4-IgG-NMOSD和MS。
核心结论
- MOGAD的MRI T2病灶比AQP4-IgG-NMOSD和MS更常完全消失,这对诊断、疾病活动监测和临床试验设计有启示。
研究设计与样本
- 回顾性描述性研究,纳入Mayo Clinic的156例患者(MOGAD 38例、AQP4-IgG-NMOSD 51例、MS 67例),共172次发作(脑81次、脊髓炎91次)。
- 纳入标准包括脑或脊髓炎发作、6周内发作期MRI、以及至少6个月后无该区域复发的随访MRI。
- 由两名神经科医生确定指示病灶,两名神经放射科医生盲法独立评估T2病灶是否消失。
主要发现
- 指示T2病灶完全消失率:MOGAD脑部13/18(72%)、脊髓22/28(79%);AQP4-IgG-NMOSD脑部3/21(14%)、脊髓0/34(0%);MS脑部7/42(17%)、脊髓0/29(0%)(p < 0.001)。
- 所有T2病灶消失率:MOGAD脑部7/18(39%)、脊髓22/28(79%);AQP4-IgG-NMOSD脑部2/21(10%)、脊髓0/34(0%);MS脑部2/42(5%)、脊髓0/29(0%)(p < 0.01)。
- 随访轴位脑MRI T2病灶面积中位缩小值:MOGAD 213 mm²(范围55-873),大于AQP4-IgG-NMOSD 104 mm²(范围0.7-597)(p = 0.02)和MS 36 mm²(范围0-506)(p < 0.001)。
- 随访矢状位脊髓MRI病灶面积中位缩小值:MOGAD 262 mm²(范围0-888)与AQP4-IgG-NMOSD 309 mm²(范围0-1885)相似(p = 0.4),均大于MS 23 mm²(范围0-152)(p < 0.001)。
- 年龄中位数(范围):MOGAD 25岁(2-74)、AQP4-IgG-NMOSD 53岁(10-78)、MS 37岁(16-61)(p < 0.01);女性比例:AQP4-IgG-NMOSD 41/51(80%)、MS 51/67(76%)、MOGAD 17/38(45%)。
临床怎么用
- MOGAD病灶更易完全消失,随访MRI评估病灶转归有助于鉴别诊断。
- 监测疾病活动时需考虑不同疾病T2病灶演变差异。
- 临床试验设计可将病灶完全消失作为MOGAD的潜在结局指标。
局限性
- 回顾性研究,样本来自单中心,可能存在选择偏倚。
- 仅纳入无interval复发的患者,可能影响病灶演变评估。
- 未报告其他可能影响病灶转归的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and understanding differences in disease pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte glycoprotein immunoglobulin G (IgG)-associated disorder (MOGAD), aquaporin 4 IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD), and multiple sclerosis (MS). METHODS: In this descriptive study, we retrospectively identified Mayo Clinic patients with MOGAD, AQP4-IgG-NMOSD, or MS and (1) brain or myelitis attack; (2) available attack MRI within 6 weeks; and (3) follow-up MRI beyond 6 months without interval relapses in that region. Two neurologists identified the symptomatic or largest T2 lesion for each patient (index lesion). MRIs were then independently reviewed by 2 neuroradiologists blinded to diagnosis to determine resolution of T2 lesions by consensus. The index T2 lesion area was manually outlined acutely and at follow-up to assess variation in size. RESULTS: We included 156 patients (MOGAD, 38; AQP4-IgG-NMOSD, 51; MS, 67) with 172 attacks (brain, 81; myelitis, 91). The age (median [range]) differed between MOGAD (25 [2-74]), AQP4-IgG-NMOSD (53 [10-78]), and MS (37 [16-61]) (p < 0.01) and female sex predominated in the AQP4-IgG-NMOSD (41/51 [80%]) and MS (51/67 [76%]) groups but not among those with MOGAD (17/38 [45%]). Complete resolution of the index T2 lesion was more frequent in MOGAD (brain, 13/18 [72%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 3/21 [14%]; spine, 0/34 [0%]) and MS (brain, 7/42 [17%]; spine, 0/29 [0%]) (p < 0.001). Resolution of all T2 lesions occurred most often in MOGAD (brain, 7/18 [39%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 2/21 [10%]; spine, 0/34 [0%]) and MS (brain, 2/42 [5%]; spine, 0/29 [0%]) (p < 0.01). There was a larger median (range) reduction in T2 lesion area in mm2 on follow-up axial brain MRI with MOGAD (213 [55-873]) than AQP4-IgG-NMOSD (104 [0.7-597]) (p = 0.02) and MS (36 [0-506]) (p < 0.001) and the reductions in size on sagittal spine MRI follow-up in MOGAD (262 [0-888]) and AQP4-IgG-NMOSD (309 [0-1885]) were similar (p = 0.4) and greater than in MS (23 [0-152]) (p < 0.001). DISCUSSION: The MRI T2 lesions in MOGAD resolve completely more often than in AQP4-IgG-NMOSD and MS. This has implications for diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS demyelinating diseases.
引用
- Sechi E, Krecke KN, Messina SA, et al. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology. 2021. PMID: 34261784. doi:10.1212/WNL.0000000000012467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。